Neurology Central

Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up

This week, we’re covering some of the latest industry headlines on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s disease and cannabidiol oral solution for seizures. Discover more about our selection of this week’s highlights below:

Cannabinoid-derived drug (Epidyolex™) gains positive CHMP opinion for seizures

GW Pharmaceuticals (CA, USA) has received a positive opinion for Epidyolex™ (cannabidiol) for its use as an adjunctive therapy alongside clobazam for seizures associated with Lennox–Gastaut syndrome (LGS), or Dravet syndrome, in patients 2 years of age and older.

“Cannabidiol oral solution is the first in a new class of epilepsy medicines and the first plant-derived cannabis-based medicine to be submitted for European regulatory review, representing a historic breakthrough,” commented Justin Gover, the Chief Executive Officer at GW Pharmaceuticals.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.